Literature DB >> 29777378

Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.

Tomofumi Miura1,2, Shuichi Mitsunaga3,4,5, Masafumi Ikeda6, Izumi Ohno6, Hideaki Takahashi6, Hidetaka Suzuki7, Ai Irisawa8, Takeshi Kuwata9, Atsushi Ochiai10.   

Abstract

PURPOSE: Acyl ghrelin is an orexigenic peptide. Active ghrelin ratio, the ratio of acyl ghrelin to total ghrelin, has an important role in physiological functions and gastrointestinal symptoms. However, low active ghrelin ratio-related characteristics, gastrointestinal symptoms, and chemotherapy-induced gastrointestinal toxicity in patients with advanced pancreatic cancer have not been previously evaluated. The goal of this study was to identify low active ghrelin ratio-related factors in treatment-naïve advanced pancreatic cancer patients.
METHODS: Patients with treatment-naïve advanced pancreatic cancer were eligible for inclusion in this study. Active ghrelin ratio and clinical parameters of patients were prospectively recorded. Factors correlated with low active ghrelin ratio and survival were analyzed.
RESULTS: In total, 92 patients were analyzed. Low active ghrelin ratio-related factors were advanced age (P < 0.01), severe appetite loss (P < 0.01), and decreased cholinesterase (P < 0.01). The adverse events of grade 2 or higher anorexia tended to increase in patients with low active ghrelin ratio. However, no differences were found in survival and body composition between low and high active ghrelin ratio groups.
CONCLUSIONS: Low active ghrelin ratio was related to lack of appetite and low cholinesterase and tended to be related to anorexia grade 2 or higher in patients with treatment-naïve advanced pancreatic cancer.

Entities:  

Keywords:  Active ghrelin ratio; Anorexia; Ghrelin; Mucositis; Pancreatic cancer

Mesh:

Substances:

Year:  2018        PMID: 29777378     DOI: 10.1007/s00520-018-4248-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  35 in total

1.  Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia.

Authors:  Josè M Garcia; Mariana Garcia-Touza; Rabih A Hijazi; George Taffet; Daniel Epner; Douglas Mann; Roy G Smith; Glenn R Cunningham; Marco Marcelli
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

2.  Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action.

Authors:  V Sibilia; G Rindi; F Pagani; D Rapetti; V Locatelli; A Torsello; N Campanini; R Deghenghi; C Netti
Journal:  Endocrinology       Date:  2003-01       Impact factor: 4.736

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Methotrexate-induced intestinal mucositis delays gastric emptying and gastrointestinal transit of liquids in awake rats.

Authors:  Pedro M G Soares; Lorena O Lopes; José Maurício S C Mota; José Nelson Belarmino-Filho; Ronaldo A Ribeiro; Marcellus Henrique L P de Souza
Journal:  Arq Gastroenterol       Date:  2011 Jan-Mar

5.  Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa.

Authors:  D Miljic; S Pekic; M Djurovic; M Doknic; N Milic; F F Casanueva; M Ghatei; V Popovic
Journal:  J Clin Endocrinol Metab       Date:  2006-01-31       Impact factor: 5.958

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept.

Authors:  B G Taal; H Boot; P van Heerde; D de Jong; A A Hart; J M Burgers
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

8.  Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.

Authors:  Shuichi Mitsunaga; Taira Kinoshita; Takahiro Hasebe; Toshio Nakagohri; Masaru Konishi; Shinichiro Takahashi; Naoto Gotohda; Atsushi Ochiai
Journal:  Pancreas       Date:  2008-04       Impact factor: 3.327

Review 9.  Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients.

Authors:  Kristine Nelson; Declan Walsh; Finbar Sheehan
Journal:  Support Care Cancer       Date:  2002-07-03       Impact factor: 3.603

10.  The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study.

Authors:  Francesco Russo; Michele Linsalata; Caterina Clemente; Benedetta D'Attoma; Antonella Orlando; Giovanna Campanella; Francesco Giotta; Giuseppe Riezzo
Journal:  BMC Cancer       Date:  2013-02-04       Impact factor: 4.430

View more
  3 in total

Review 1.  Diverse and Complementary Effects of Ghrelin and Obestatin.

Authors:  Daniel Villarreal; Geetali Pradhan; Yu Zhou; Bingzhong Xue; Yuxiang Sun
Journal:  Biomolecules       Date:  2022-03-29

Review 2.  Attribution of Ghrelin to Cancer; Attempts to Unravel an Apparent Controversy.

Authors:  Saeed Soleyman-Jahi; Fatemeh Sadeghi; Amin Pastaki Khoshbin; Leila Khani; Venus Roosta; Kazem Zendehdel
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

Review 3.  The Benefits of Olanzapine in Palliating Symptoms.

Authors:  Mellar P Davis; Gareth J Sanger
Journal:  Curr Treat Options Oncol       Date:  2020-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.